Blame It On COVID: Alkermes CRL Tied To Remote Site Inspections

Alkermes’ combo pill for schizophrenia and bipolar disorder received an FDA complete response due to manufacturing questions that a physical site review might have resolved.

Hand drawn failure in business. Unfortunate attempt to hit the target
Alkermes gets a complete response letter but it's only CMC issues that are off-target

Alkermes plc announced receipt of a complete response letter from the US Food and Drug Administration for its new drug application for ALKS 3831 for schizophrenia and bipolar disorder on 17 November due to a manufacturing issue. The FDA denied approval by the 15 November action date, not because of safety and efficacy questions but because the FDA could not conduct a physical site inspection due to the COVID-19 pandemic.

On a same-day investor call, Alkermes CEO Richard Pops said he hopes the company can quickly submit data showing resolution...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip